Latest News

Upcoming Events

Partnering

 

It is Genmab’s belief that the DuoBody® platform will be the preferred technology for bispecific antibody therapeutics

Genmab’s passion for science-based development of antibody therapeutics has driven the successful development of the DuoBody technology. 
DuoBody highlights:
• The DuoBody technology is ideally suited for the generation of bispecific IgG1 antibodies with regular human IgG1 structure and using minimal protein engineering (via single mutations).
 - The immunogenicity risk profile of bispecific human IgG1 antibodies generated with the DuoBody platform is very low.
 - DuoBody IgG1 molecules fully retain Fc-mediated effector functions, including complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
 - The in vivo serum half-life of DuoBody antibodies is similar to that of wild-type human IgG1.
 • The DuoBody technology can be extended to other human IgG subclasses to suit particular applications.
• Using the DuoBody technology, novel and existing antigen binding sequences derived from any antibody-generating platform can be combined into a bispecific product.
• The versatile in vitro post-production exchange reaction makes the DuoBody platform highly suitable for high-throughput generation, screening, and discovery of bispecific antibodies in the final format.
• The DuoBody large-scale manufacturing process is compatible with standard unit operations for IgG. Simple upscaling of the bench scale protocol to large scale results in a high yield of bispecific antibody with excellent quality and stability.
• The DuoBody technology has potential beyond the generation of bispecific antibodies, e.g. bispecific antibody drug conjugates or combined Fc-fusion proteins.

Back to top

 

Genmab is actively seeking partners interested in developing bispecific antibody therapeutics incorporating the DuoBody® technology

Genmab is particularly interested in the possibility of co-development or opt-in scenarios for products in oncology or hematology, in addition to traditional licensing in exchange for upfront payments, milestones and royalties.

To date, Genmab has licensed the DuoBody technology on a program-by-program basis where each program is defined by a combination of two targets (or two epitopes from the same target).
For the DuoBody technology we have five ongoing commercial collaborations with Janssen, Novartis, Aduro Biotech Europe, BioNTech, and Novo Nordisk and ongoing research collaborations with Gilead, Eli Lily and Company, and Agenus.

Our first license was a research collaboration with an undisclosed, large pharmaceutical partner to investigate a bispecific antibody-drug conjugate using Genmab's DuoBody technology in combination with a novel antibody-drug conjugate technology platform from the pharmaceutical company. This collaboration was completed as planned and both parties have decided not to enter into a license agreement to develop a DuoBody-ADC product.

Novartis licensed the DuoBody technology with options to commercialize two bispecific programs, in a deal signed in June 2012 that included an upfront payment of USD 2M with a total potential deal value of USD 175M plus research funding and royalties.

One month later, July 2012, we entered the agreement with Janssen, where we received an upfront payment of USD 3.5M. This agreement was expanded to include additional programs in December 2013. The Janssen agreement has a potential value of approximately USD 3.6B if all programs are successful. Janssen is fully funding all development and we have the potential to receive milestone payments of approximately USD 175M to USD 219M per product (depending on the date each program is initiated) in addition to royalties on any commercialized project. We have not, as yet, disclosed any further details, except that we have already achieved a technical proof of concept and a milestone payment for pre-clinical progress on the EM1-mAb Janssen DuoBody product which targets EGFr and cMet, two validated targets for cancer therapy. Click here to watch a video describing what has made this a successful collaboration.

The deals with Novartis and Janssen include funding for a number of FTEs at Genmab to support development of their DuoBody programs. Novartis and Janssen will be responsible for all development costs for their potential DuoBody products.

KHK has a research license to the technology which could be converted to a commercial license in due course if the parties so wish. Eli Lilly and Company entered into a research collaboration to use and evaluate the DuoBody technology platform for the creation of bispecific antibodies. Under the collaboration, Lilly will initially evaluate the DuoBody technology platform in house, and may consider entering a commercial license agreement if the evaluation is successful. We also have entered into other research collaborations that could evolve into a commercial partnership with Cormorant, Agenus (for immuno-oncology targets) and an undisclosed major biotech company.

Genmab is also pursuing clinical development of our own products using the DuoBody technology. We may continue to develop such products all the way to commercialization, or we may partner. By retaining sole control of development for a longer period, we hold on to a larger share of product value. None of the products we are developing ourselves are as yet available for partnering.

We also continue to actively license the DuoBody technology on a program-by-program basis to partners that have their own product concepts, perhaps already including antibody panels, to which the DuoBody technology can be applied immediately.
 
Click here to request more information.

Back to top

 

Evaluation licenses available

Therapeutics based on bispecific antibody technology, such as the DuoBody technology, have potential application in multiple disease areas. We believe this makes the DuoBody technology of particular interest to life science companies. To allow life science companies to evaluate the DuoBody technology before making a commitment to bring products into the clinic, Genmab can provide technology evaluation licenses. These licenses permit in-depth investigation of multiple DuoBody product concepts in a non-clinical setting.

Genmab is particularly interested in joint development or obtaining an option to participate in joint development at a later stage for DuoBody products that fall within our target therapeutic areas such as hematology and oncology.

Click here for more information .

Back to top